A Phase I Clinical Study of the Safety, Pharmacokinetics, and Antitumor Activity of SSS59 in Patients With Advanced Malignant Tumors
Latest Information Update: 06 May 2025
At a glance
- Drugs Mucin inhibitors (Primary)
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Shenyang Sunshine Pharmaceutical
Most Recent Events
- 06 May 2025 New trial record
- 29 Apr 2025 Status changed from not yet recruiting to recruiting.